ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2023
A 95% decline in estimated newly acquired HIV infections, Amsterdam, 2010 to 2022.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Characterising individuals with newly diagnosed HIV before versus during the era of PrEP: a descriptive time-series analysis of data from a sexual health centre in Amsterdam, the Netherlands, 2015 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- The HIV/AIDS response as we knew it is over: Where do we go from here?Journal of the International AIDS Society · 2026Review
- HIV treatment cascade and associated factors among men who have sex with men in Brazil: a cross-sectional study.Scientific reports · 2026Article
- Time series analysis of new HIV diagnoses in France from 2012 to 2022.Epidemiology and infection · 2026Article
- From exceptionalism to universal testing: an historical review of HIV testing in Portugal.BMC public health · 2025Review
- Using linked national registry data and the ECDC HIV modelling tool to estimate HIV incidence and the proportion diagnosed in Norway up to 2023.BMC infectious diseases · 2025Article
- Epidemiological impact and cost-effectiveness analysis of PrEP provision expansion among MSM in the Netherlands.Journal of the International AIDS Society · 2025Article
- Progress towards the UNAIDS 2030 HIV prevention target in New South Wales, Australia: a population-based study.The Lancet regional health. Western Pacific · 2025Article
- Advances in HIV management and challenges in Japan: Current situation of pre-exposure prophylaxis in Tokyo.Global health & medicine · 2024Review
- Sources of Human Immunodeficiency Virus Infections Among Men Who Have Sex With Men With a Migration Background: A Viral Phylogenetic Case Study in Amsterdam, The Netherlands.The Journal of infectious diseases · 2024Article
- Is HIV epidemic control by 2030 realistic?The lancet. HIV · 2024Review
- The potential of broadly neutralizing antibodies for HIV prevention.Journal of the International AIDS Society · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The infrastructure in cities provides unique opportunities to eliminate HIV. Since 2014, the HIV Transmission Elimination AMsterdam Initiative, a consortium involved in HIV prevention and care, has employed an integrated approach to curb HIV incidence in Amsterdam. This effort contributed to the 95% decline in estimated newly acquired infections and the 79% decline in observed new HIV diagnoses in Amsterdam from 2010 to 2022. In 2022, Amsterdam reached and exceeded the 95-95-95 UNAIDS treatment cascade goals (98-95%-96%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.